This study “provides compelling evidence for incorporating oncology-trained pharmacists into hematology-oncology care teams,” researchers wrote.

To our knowledge, the SOGUG-AUREA trial showed, for the first time, that the combination of atezolizumab with split doses of cisplatin and gemcitabine was effective and safe for patients with mUC ,” ...

US health officials have informed leading medical organizations that they will no longer be invited to participate in developing vaccination recommendations.

The One Big Beautiful Bill Act will have negative impacts on cancer patients, oncologists, and the health care system at large, experts say.

Survey results suggest that some patients with multiple myeloma may forgo treatment that improves progression-free survival (PFS) if it also increases the risk of adverse events and fails to improve ...

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.

The FDA has accepted for priority review the sBLA for lisocabtagene maraleucel to treat relapsed/refractory MZL.

The HHS secretary has canceled nearly $500 million in grants and contracts intended to support mRNA vaccine development.

The executive order outlines some of the steps the Trump administration has already taken to delay or withhold federal funding and terminate existing grants. However, those actions have been ...

Recent news reports highlight uncertainty about pharmaceutical tariffs, an error-prone AI tool in use at the FDA, and scientific research funding in jeopardy.

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of certain patients with diffuse midline glioma.